Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, today announced results for the
quarter ended September 30, 2017.
Quarter 3 Results
Total revenues for Q3, 2017 were $25.6m which is
broken down as follows:
|
2016Quarter 3 |
2017Quarter 3 |
Increase/
(decrease) |
|
US$’000 |
US$’000 |
% |
Point-of-Care |
4,903 |
4,598 |
(6.2 |
%) |
Clinical Laboratory |
21,224 |
21,006 |
(1.0 |
%) |
Total |
26,127 |
25,604 |
(2.0 |
%) |
Point-of-Care revenues for Q3, 2017 decreased
from $4.9m to $4.6m. This was primarily due to lower sales of HIV
products in Africa.
Meanwhile, Clinical Laboratory sales for the
quarter were $21.0m versus $21.2m for the corresponding period last
year, thus representing a decrease of 1.0%. However, when the
impact of recently culled products is taken into account,
underlying Clinical Laboratory sales increased by approximately
2.6%. This growth was mainly driven by higher Premier
revenues, including the impact of Premier Resolution, as well as
higher autoimmune sales largely driven by strong laboratory
services revenues.
The gross margin for the quarter was 43%, which
compares to 44.7% in Q3, 2016. This decrease is largely due to
lower high margin point-of-care revenues and foreign exchange
factors, including the impact of exchange rates on distributor
pricing. Whilst the gross margin is lower than in the comparative
period it continues the trend of sequentially improving gross
margins witnessed in recent quarters.
Research and Development expenses increased from
$1.3m in Q3, 2016 to $1.5m in Q3, 2017. Meanwhile, Selling, General
and Administrative (SG&A) expenses increased from $7.5m to
$7.8m in Q3, 2017, an increase of approximately 3%. This increase
was due to normal inflationary pressures and higher discretionary
sales and marketing expenses such as trade shows and travel
costs.
Operating profit for the quarter decreased from
$2.7m to $1.5m. This was due to the combined impact of the lower
revenues and gross margin and the higher indirect costs incurred
during the quarter.
Both financial income and interest payable for
the quarter remained static at $0.2m and $1.2m respectively. The
interest payable arises mainly on the Company’s exchangeable
notes. A further non-cash expense of $0.1m was recognised in
this quarter’s income statement, again in relation to the
exchangeable notes. This was due to a non-cash interest
charge of $0.2m partially offset by a gain of $0.1m arising on a
decrease in the fair value of the derivatives embedded in these
notes.
Overall, the Company recorded a profit of $0.4m
for the quarter, which equates to earnings per share of 2.1
cents. However, excluding non-cash items the profit for the
quarter was $0.5m or an EPS of 2.4 cents. Fully diluted EPS for the
quarter was 6.3 cents compared to 9.7 cents in Q3, 2016.
EBITDA before share option expense for the
quarter was $3.1m.
Share Buyback
During the quarter, the Company repurchased
281,000 ADRs at an average price of $5.49 and with a total value of
$1.5m. This brings the total purchased since the beginning of the
program to approximately 2.1m shares with a total value of
$15.8m.
Comments
Commenting on the results, Kevin Tansley, Chief
Financial Officer, said “This quarter we demonstrated continued
progress from a financial perspective. As well achieving underlying
growth in our Clinical Laboratory revenues, we also reported an
increase in gross margins for the third quarter in a row. However,
this has not immediately translated into higher profits as our
indirect costs were slightly higher this quarter, due to increased
investment in both R&D and sales and marketing activities as we
seek to drive future revenue growth. Another positive aspect was
that we generated positive free cash flows this quarter, thus
reflecting the improved cash flows of the Company following the
suspension of the Meritas project in late 2016.”
Ronan O’Caoimh, CEO of Trinity said “This
quarter underlying growth in our key Clinical Laboratory segment
was driven by higher haemoglobin and autoimmune revenues. Our
haemoglobin revenues are now being boosted by new sales of our
recently launched Premier Resolution instrument, which specifically
targets the haemogloblin variant market. This instrument is
building on the continued success of our Premier 9210 Diabetes
instrument, which is now the market leader in a number of
countries. Meanwhile, our autoimmune revenues are increasing as we
grow our laboratory services business through a combination of
increased testing menu and the ongoing development of key
commercial relationships. We continue to retain our
pre-eminent position in the confirmatory HIV testing market in
Africa and whilst revenues were down this quarter, year to date
sales are in line with last year. Future growth opportunities in
the HIV market will come from our forthcoming entry into the HIV
screening market in Africa.
We believe that the current strength of our
product portfolio and the growth opportunities inherent in our
business are not fully reflected in our current share price.
Consequently we remain committed to buying back a significant
number of Trinity shares at these levels.”
Forward-looking statements in this release are
made pursuant to the "safe harbor" provision of the Private
Securities Litigation Reform Act of 1995. Investors are
cautioned that such forward-looking statements involve risks and
uncertainties including, but not limited to, the results of
research and development efforts, the effect of regulation by the
United States Food and Drug Administration and other agencies, the
impact of competitive products, product development
commercialisation and technological difficulties, and other risks
detailed in the Company's periodic reports filed with the
Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
|
Trinity Biotech plc |
Consolidated Income Statements |
|
|
|
|
|
|
(US$000’s except
share data) |
|
Three Months Ended
September 30,
2017(unaudited) |
|
Three Months
Ended September
30,
2016(unaudited) |
|
Nine Months
Ended September
30,
2017(unaudited) |
|
Nine Months
Ended September
30,
2016(unaudited) |
|
|
|
|
|
|
|
Revenues |
|
25,604 |
|
26,127 |
|
74,588 |
|
75,931 |
|
|
|
|
|
|
|
Cost of sales |
|
(14,606 |
) |
(14,460 |
) |
(42,889 |
) |
(42,316 |
) |
|
|
|
|
|
|
Gross
profit |
|
10,998 |
|
11,667 |
|
31,699 |
|
33,615 |
|
Gross margin % |
|
43.0 |
% |
44.7 |
% |
42.5 |
% |
44.3 |
% |
|
|
|
|
|
|
Other operating
income |
|
25 |
|
70 |
|
73 |
|
211 |
|
|
|
|
|
|
|
Research & development expenses |
|
(1,469 |
) |
(1,296 |
) |
(4,119 |
) |
(3,711 |
) |
Selling, general and
administrative expenses |
|
(7,761 |
) |
(7,487 |
) |
(22,341 |
) |
(22,245 |
) |
Indirect share based
payments |
|
(265 |
) |
(236 |
) |
(644 |
) |
(971 |
) |
|
|
|
|
|
|
Operating
profit |
|
1,528 |
|
2,718 |
|
4,668 |
|
6,899 |
|
|
|
|
|
|
|
Financial income |
|
212 |
|
212 |
|
584 |
|
657 |
|
Financial expenses |
|
(1,168 |
) |
(1,179 |
) |
(3,506 |
) |
(3,545 |
) |
Net financing
expense |
|
(956 |
) |
(967 |
) |
(2,922 |
) |
(2,888 |
) |
|
|
|
|
|
|
Profit before
tax & non-cash financial income / (expense) |
|
572 |
|
1,751 |
|
1,746 |
|
4,011 |
|
|
|
|
|
|
|
Income tax expense |
|
(56 |
) |
(148 |
) |
(331 |
) |
(462 |
) |
|
|
|
|
|
|
|
|
|
|
Profit for the
period before non-cash financial income / (expense) |
|
516 |
|
1,603 |
|
1,415 |
|
3,549 |
|
|
|
|
|
|
|
|
|
|
|
Non-cash financial
income / (expense) |
|
(71 |
) |
(2,120 |
) |
1,178 |
|
(3,308 |
) |
|
|
|
|
|
|
|
|
|
|
Profit / (loss)
after tax and once-off items |
|
445 |
|
(517 |
) |
2,593 |
|
241 |
|
|
|
|
|
|
|
|
|
|
|
Earnings per ADR (US
cents) |
|
2.1 |
|
(2.3 |
) |
11.9 |
|
1.0 |
|
|
|
|
|
|
|
|
|
|
|
Earnings per ADR
excluding non-cash financial income (US cents) |
|
2.4 |
|
7.0 |
|
6.5 |
|
15.4 |
|
|
|
|
|
|
|
Diluted earnings per
ADR (US cents) |
|
6.3* |
|
9.7* |
|
18.0* |
|
24.6* |
|
|
|
|
|
|
|
Weighted average no. of
ADRs used in computing basic earnings per ADR |
|
21,379,422 |
|
22,797,208 |
|
21,773,874 |
|
23,032,885 |
|
|
|
|
|
|
|
Weighted average no. of
ADRs used in computing diluted earnings per ADR |
|
26,636,857 |
|
28,379,444 |
|
27,031,396 |
|
28,452,580 |
|
|
|
|
|
|
|
* Under IAS 33 Earnings per Share, diluted
earnings per share cannot be anti-dilutive. In a reporting period
where it is anti-dilutive, diluted earnings per ADR should be
constrained to equal basic earnings per ADR.
The above financial statements have been
prepared in accordance with the principles of International
Financial Reporting Standards and the Company’s accounting policies
but do not constitute an interim financial report as defined in IAS
34 (Interim Financial Reporting).
|
Trinity Biotech plc |
Consolidated Balance Sheets |
|
|
|
|
|
|
September 30,2017US$
‘000(unaudited) |
|
June 30,2017US$
‘000(unaudited) |
|
March 31,2017US$
‘000(unaudited) |
|
Dec 31,2016US$
‘000(unaudited) |
|
ASSETS |
|
|
|
|
Non-current
assets |
|
|
|
|
Property, plant and
equipment |
15,191 |
|
14,462 |
|
14,163 |
|
13,403 |
|
Goodwill and intangible
assets |
92,185 |
|
90,438 |
|
88,996 |
|
87,275 |
|
Deferred tax
assets |
15,074 |
|
15,352 |
|
14,669 |
|
14,556 |
|
Other assets |
904 |
|
873 |
|
828 |
|
870 |
|
Total
non-current assets |
123,354 |
|
121,125 |
|
118,656 |
|
116,104 |
|
|
|
|
|
|
Current
assets |
|
|
|
|
Inventories |
32,711 |
|
33,620 |
|
32,659 |
|
32,589 |
|
Trade and other
receivables |
24,603 |
|
24,856 |
|
22,683 |
|
22,586 |
|
Income tax
receivable |
1,427 |
|
1,220 |
|
1,290 |
|
1,205 |
|
Cash and cash
equivalents |
62,529 |
|
63,977 |
|
69,851 |
|
77,108 |
|
Total current
assets |
121,270 |
|
123,673 |
|
126,483 |
|
133,488 |
|
|
|
|
|
|
TOTAL
ASSETS |
244,624 |
|
244,798 |
|
245,139 |
|
249,592 |
|
|
|
|
|
|
EQUITY AND
LIABILITIES |
|
|
|
|
Equity
attributable to the equity holders of the parent |
|
|
|
|
Share capital |
1,224 |
|
1,176 |
|
1,176 |
|
1,224 |
|
Share premium |
16,077 |
|
16,122 |
|
16,122 |
|
16,187 |
|
Accumulated
surplus |
89,878 |
|
90,977 |
|
93,171 |
|
93,004 |
|
Other reserves |
(792 |
) |
(1,409 |
) |
(1,193 |
) |
(1,688 |
) |
Total
equity |
106,387 |
|
106,866 |
|
109,276 |
|
108,727 |
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
Income tax payable |
502 |
|
582 |
|
181 |
|
175 |
|
Trade and other
payables |
22,923 |
|
22,572 |
|
20,893 |
|
25,028 |
|
Provisions |
75 |
|
75 |
|
75 |
|
75 |
|
Total current
liabilities |
23,500 |
|
23,229 |
|
21,149 |
|
25,278 |
|
|
|
|
|
|
Non-current
liabilities |
|
|
|
|
Exchangeable senior
note payable |
95,316 |
|
95,245 |
|
95,462 |
|
96,491 |
|
Other payables |
582 |
|
640 |
|
698 |
|
735 |
|
Deferred tax
liabilities |
18,839 |
|
18,818 |
|
18,554 |
|
18,361 |
|
Total
non-current liabilities |
114,737 |
|
114,703 |
|
114,714 |
|
115,587 |
|
|
|
|
|
|
TOTAL
LIABILITIES |
138,237 |
|
137,932 |
|
135,863 |
|
140,865 |
|
|
|
|
|
|
TOTAL EQUITY
AND LIABILITIES |
244,624 |
|
244,798 |
|
245,139 |
|
249,592 |
|
|
|
|
|
|
|
|
|
|
The above financial statements have been
prepared in accordance with the principles of International
Financial Reporting Standards and the Company’s accounting policies
but do not constitute an interim financial report as defined in IAS
34 (Interim Financial Reporting).
|
Trinity Biotech plc |
Consolidated Statement of Cash
Flows |
|
|
|
|
|
(US$000’s) |
Three Months
Ended September
30,
2017(unaudited) |
|
Three Months
Ended September
30, 2016
(unaudited) |
|
Nine Months
Ended September
30, 2017
(unaudited) |
|
Nine Months
Ended September
30, 2016
(unaudited) |
|
|
|
|
|
|
Cash and cash
equivalents at beginning of period |
63,977 |
|
84,920 |
|
77,109 |
|
101,953 |
|
|
|
|
|
|
Operating cash flows
before changes in working capital |
3,672 |
|
5,164 |
|
9,679 |
|
12,950 |
|
Changes in working
capital |
313 |
|
393 |
|
(2,262 |
) |
(3,469 |
) |
Cash generated from
operations |
3,985 |
|
5,557 |
|
7,417 |
|
9,481 |
|
|
|
|
|
|
Net Interest and Income
taxes (paid)/received |
86 |
|
(171 |
) |
324 |
|
(263 |
) |
|
|
|
|
|
Capital Expenditure
& Financing (net) |
(3,727 |
) |
(5,555 |
) |
(10,559 |
) |
(16,982 |
) |
|
|
|
|
|
Free cash flow |
344 |
|
(169 |
) |
(2,818 |
) |
(7,764 |
) |
|
|
|
|
|
Share buyback |
(1,543 |
) |
- |
|
(6,472 |
) |
(6,026 |
) |
|
|
|
|
|
Payment of HIV-2
licence fee |
- |
|
- |
|
(1,112 |
) |
(1,112 |
) |
|
|
|
|
|
30 year Exchangeable
Note interest payment |
- |
|
- |
|
(2,300 |
) |
(2,300 |
) |
|
|
|
|
|
Once-off items |
(249 |
) |
- |
|
(1,878 |
) |
- |
|
|
|
|
|
|
Cash and cash
equivalents at end of period |
62,529 |
|
84,751 |
|
62,529 |
|
84,751 |
|
|
|
|
|
|
The above financial statements have been
prepared in accordance with the principles of International
Financial Reporting Standards and the Company’s accounting policies
but do not constitute an interim financial report as defined in IAS
34 (Interim Financial Reporting).
Contact:
Trinity Biotech plcKevin
Tansley(353)-1-2769800E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLCJoe Diaz, Joe
Dorame & Robert Blum602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024